Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#141 / 200 Total
GMAB - Genmab ADR - Stock Price Chart
TickerGMAB [NASD]
CompanyGenmab ADR
CountryDenmark
IndustryBiotechnology
Market Cap19.32BEPS (ttm)1.21
P/E24.50EPS this Y21.41%
Forward P/E20.10EPS next Y27.09%
PEG1.87EPS past 5Y20.52%
P/S7.48EPS next 5Y13.10%
P/B4.09EPS Q/Q494.74%
Dividend-Sales Q/Q46.59%
Insider Own0.00%Inst Own7.18%
Insider Trans-Inst Trans23.77%
Short Float0.40%EarningsMay 02/a
Analyst Recom2.00Target Price39.30
Avg Volume566.27K52W Range26.32 - 42.72
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
LLYVA - Liberty Media Corp. - Stock Price Chart
TickerLLYVA [NASD]
CompanyLiberty Media Corp.
CountryUSA
IndustryEntertainment
Market Cap3.49BEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own97.32%Inst Own26.39%
Insider Trans77.58%Inst Trans-
Short Float33.67%EarningsMay 08/b
Analyst Recom1.00Target Price56.00
Avg Volume198.11K52W Range29.48 - 43.24
Operates as a holding company providing live entertainment
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERKSHIRE HATHAWAY INC10% OwnerApr 29 '24Buy25.47311,6377,936,27270,002,897May 01 07:03 PM
BERKSHIRE HATHAWAY INC10% OwnerApr 26 '24Buy24.34277,2486,747,85669,691,260Apr 26 08:20 PM
BERKSHIRE HATHAWAY INC10% OwnerApr 26 '24Buy24.46219,3035,364,32735,182,219Apr 26 08:22 PM
BERKSHIRE HATHAWAY INC10% OwnerApr 25 '24Buy24.36227,4695,541,64569,414,012Apr 26 08:20 PM
BERKSHIRE HATHAWAY INC10% OwnerApr 25 '24Buy24.43157,3093,842,68134,962,916Apr 26 08:22 PM
DHC - Diversified Healthcare Trust - Stock Price Chart
TickerDHC [NASD, RUT]
CompanyDiversified Healthcare Trust
CountryUSA
IndustryREIT - Healthcare Facilities
Market Cap620.28MEPS (ttm)-1.23
P/E-EPS this Y6.88%
Forward P/E-EPS next Y27.62%
PEG-EPS past 5Y-
P/S0.44EPS next 5Y3.20%
P/B0.27EPS Q/Q-56.61%
Dividend1.55%Sales Q/Q7.32%
Insider Own10.32%Inst Own76.04%
Insider Trans0.00%Inst Trans-2.21%
Short Float3.32%EarningsMay 06/a
Analyst Recom3.00Target Price3.50
Avg Volume1.11M52W Range0.80 - 3.96
Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants. The SHOP segment manages senior living communities that offers short term and long term residential care, and other services for residents where it pay fees to the operator to manage the communities for its account. The company was founded on December 16, 1998 and is headquartered in Newton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PORTNOY ADAM D.DirectorJun 14 '23Buy3.072,000,0006,132,60023,250,019Jun 14 06:23 PM
PORTNOY ADAM D.DirectorJun 13 '23Buy3.031,992,2596,026,78321,250,019Jun 14 06:23 PM
PORTNOY ADAM D.DirectorJun 12 '23Buy2.872,011,2565,778,54019,257,760Jun 14 06:23 PM
PORTNOY ADAM D.DirectorJun 09 '23Buy2.591,905,2004,943,23217,246,504Jun 09 06:12 PM
PORTNOY ADAM D.DirectorJun 08 '23Buy2.461,690,0004,163,82215,341,304Jun 09 06:12 PM
PSNL - Personalis Inc - Stock Price Chart
TickerPSNL [NASD]
CompanyPersonalis Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap86.10MEPS (ttm)-2.25
P/E-EPS this Y29.83%
Forward P/E-EPS next Y12.03%
PEG-EPS past 5Y-28.46%
P/S1.17EPS next 5Y-13.70%
P/B0.66EPS Q/Q20.18%
Dividend-Sales Q/Q17.66%
Insider Own17.70%Inst Own42.17%
Insider Trans-0.37%Inst Trans-3.30%
Short Float2.58%EarningsMay 08/a
Analyst Recom1.33Target Price4.60
Avg Volume322.61K52W Range0.89 - 2.60
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moore Stephen MichaelSVP and Chief Legal OfficerApr 30 '24Sale1.374,5236,19772,397May 02 05:52 PM
MYERS WOODROW A JRDirectorMar 01 '24Buy1.6710,00016,70026,116Mar 05 05:15 PM
Tachibana AaronCFO AND COOJan 29 '24Sale1.37716981184,521Jan 31 04:27 PM
Chen RichardCHIEF MEDICAL OFFICER AND EVPJan 29 '24Sale1.37526721128,870Jan 31 04:30 PM
Tachibana AaronCFO and COODec 15 '23Sale1.476,7479,918185,237Dec 19 06:07 PM
OCUL - Ocular Therapeutix Inc - Stock Price Chart
TickerOCUL [NASD, RUT]
CompanyOcular Therapeutix Inc
CountryUSA
IndustryBiotechnology
Market Cap929.68MEPS (ttm)-1.26
P/E-EPS this Y17.45%
Forward P/E-EPS next Y-3.15%
PEG-EPS past 5Y8.38%
P/S15.91EPS next 5Y-
P/B7.89EPS Q/Q-71.51%
Dividend-Sales Q/Q5.16%
Insider Own9.13%Inst Own45.25%
Insider Trans21.76%Inst Trans-1.60%
Short Float10.85%EarningsMay 07/a
Analyst Recom1.38Target Price15.50
Avg Volume2.60M52W Range2.00 - 11.31
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUMMER ROAD LLC10% OwnerFeb 26 '24Buy7.52930,8517,000,0008,591,401Feb 27 04:43 PM
Mattessich Antony C.President and CEOJan 31 '24Sale4.9518,33890,773427,943Feb 02 07:00 PM
Ozden Rabia GursesChief Medical OfficerJan 31 '24Sale4.957,76438,43292,767Feb 02 07:02 PM
Strassburger Philip C.General CounselJan 31 '24Sale4.956,83133,813109,218Feb 02 07:01 PM
Notman DonaldChief Financial OfficerJan 31 '24Sale4.956,43331,843139,932Feb 02 07:03 PM
ANGI - Angi Inc - Stock Price Chart
TickerANGI [NASD]
CompanyAngi Inc
CountryUSA
IndustryInternet Content & Information
Market Cap1.31BEPS (ttm)-0.08
P/E-EPS this Y100.27%
Forward P/E42.97EPS next Y28178.04%
PEG-EPS past 5Y-
P/S0.91EPS next 5Y-
P/B1.26EPS Q/Q89.59%
Dividend-Sales Q/Q-31.96%
Insider Own86.60%Inst Own12.74%
Insider Trans-0.02%Inst Trans-0.36%
Short Float14.52%EarningsMay 07/a
Analyst Recom1.44Target Price4.25
Avg Volume858.54K52W Range1.54 - 4.18
Angi, Inc. engages in the provision of a digital marketplace for home services. It operates through the following segments: Ads and Leads, Services, Roofing, and International. The Ads and Leads segment provides service professionals the capability to engage with potential customers, including quote and invoicing services, and provides consumers with tools and resources to help them find local, pre-screened and customer-rated service professionals nationwide for home repair, maintenance and improvement projects. The Services segment includes the provision of services through the Angi platform. Angi fulfills the request through the use of independently established home service providers engaged in a trade, occupation and/or business that customarily provides such services. The Roofing segment includes roof replacement and repair services through its wholly-owned subsidiary, Angi Roofing, LLC. The international segment consists of Europe and Canada. The company was founded on April 13, 2017 and is headquartered in Denver, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shanmugasundaram KuleshChief Technology OfficerMay 01 '24Sale2.1311,74825,023160,506May 01 04:43 PM
Shanmugasundaram KuleshChief Technology OfficerApr 19 '24Option Exercise0.0012,7070178,741Apr 22 09:29 PM
Shaw ShannonChief Legal OfficerApr 01 '24Option Exercise0.00107,7510461,407Apr 01 05:34 PM
Shanmugasundaram KuleshChief Technology OfficerApr 01 '24Sale2.5811,74830,310166,034Apr 02 05:02 PM
Shanmugasundaram KuleshChief Technology OfficerMar 25 '24Option Exercise0.0036,2050196,265Mar 25 06:08 PM
BNTC - Benitec Biopharma Inc - Stock Price Chart
TickerBNTC [NASD]
CompanyBenitec Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap24.48MEPS (ttm)-10.90
P/E-EPS this Y82.79%
Forward P/E-EPS next Y27.98%
PEG-EPS past 5Y66.41%
P/S407.92EPS next 5Y-
P/B1.58EPS Q/Q20.94%
Dividend-Sales Q/Q-100.00%
Insider Own6.81%Inst Own103.68%
Insider Trans0.00%Inst Trans-
Short Float0.51%EarningsFeb 13/b
Analyst Recom1.00Target Price16.00
Avg Volume86.09K52W Range1.86 - 9.46
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.
IMNM - Immunome Inc - Stock Price Chart
TickerIMNM [NASD]
CompanyImmunome Inc
CountryUSA
IndustryBiotechnology
Market Cap952.06MEPS (ttm)-5.38
P/E-EPS this Y67.51%
Forward P/E-EPS next Y-24.26%
PEG-EPS past 5Y-48.48%
P/S67.91EPS next 5Y-
P/B5.75EPS Q/Q-508.80%
Dividend-Sales Q/Q-
Insider Own19.07%Inst Own37.02%
Insider Trans0.00%Inst Trans-0.12%
Short Float7.76%EarningsMar 28/a
Analyst Recom1.00Target Price32.50
Avg Volume835.40K52W Range4.50 - 30.96
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOOct 02 '23Buy5.91169,204999,996319,636Oct 04 05:35 PM
Turner BruceChief Strategy OfficerOct 02 '23Buy5.9142,300249,99342,300Oct 04 05:32 PM
NU - Nu Holdings Ltd - Stock Price Chart
TickerNU [NYSE]
CompanyNu Holdings Ltd
CountryCayman Islands
IndustryBanks - Regional
Market Cap55.64BEPS (ttm)0.21
P/E54.99EPS this Y65.20%
Forward P/E19.62EPS next Y53.26%
PEG-EPS past 5Y-
P/S7.94EPS next 5Y-
P/B8.69EPS Q/Q216.72%
Dividend-Sales Q/Q92.33%
Insider Own43.30%Inst Own45.80%
Insider Trans0.00%Inst Trans-2.37%
Short Float2.15%EarningsMay 14/a
Analyst Recom1.94Target Price11.90
Avg Volume27.82M52W Range5.14 - 12.39
Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Velez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.
GGB - Gerdau S.A. ADR - Stock Price Chart
TickerGGB [NYSE]
CompanyGerdau S.A. ADR
CountryBrazil
IndustrySteel
Market Cap5.30BEPS (ttm)0.71
P/E5.45EPS this Y-35.82%
Forward P/E8.47EPS next Y1.73%
PEG-EPS past 5Y19.48%
P/S0.38EPS next 5Y-1.50%
P/B0.80EPS Q/Q-49.64%
Dividend4.43%Sales Q/Q-13.13%
Insider Own0.00%Inst Own25.58%
Insider Trans-Inst Trans-
Short Float0.28%EarningsMay 02/a
Analyst Recom1.67Target Price4.72
Avg Volume8.58M52W Range3.42 - 5.04
Gerdau SA engages in the production and commercialization of steel products. It operates through the following segments: Brazil Operation, North America Operation, South Africa Operation, and Special Steels Operation. The Brazil Operation segment includes rebar, bars, shapes, drawn products, billets, blooms, slabs; wire rod, structural shapes, and iron ore. The North America Operation segment consists of rebar, bars, wire rod, and light and heavy structural shapes. The South Africa Operation segment covers rebar, bars, and drawn products. The Special Steels Operation segment comprises of stainless steel, round, square and flat bars, and wire rod. The company was founded by Joao Gerdau and Hugo Gerdau on January 16, 1901 and is headquartered in Sao Paulo, Brazil.
11011121314151617181920